Benign Prostatic Hyperplasia Therapeutics Market Expected to Reach $20,097 million by 2025
According to a new report published by Allied Market Research, titled, Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class and Therapy: Global Opportunity Analysis and Industry Forecast, 2018-2025," the market was valued at $10,689 million in 2017, and is projected to reach $20,097 million in 2025, registering a CAGR of 8.1% from 2018 to 2025.Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4708
Benign prostatic hyperplasia (BPH) is a medical condition in which a males prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor.
know more: https://www.alliedmarketresearch.com/benign-prostatic-hyperplasia-therapeutics-market
These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.
Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.
The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.
The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combination drug therapy segment is anticipated to record a high CAGR during the forecast period.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4708
Key findings of the Benign Prostatic Hyperplasia Therapeutics Market:
The phosphodiesterase-5 inhibitor segment accounted for nearly one-sixth share of the global benign prostatic hyperplasia therapeutics market in 2017.
The mono drug therapy segment is expected to grow at a CAGR of 7.6% from 2018 to 2025.
Europe accounted for around one-third share of the global market in 2017.
LAMEA is expected to provide lucrative market growth opportunities and grow at a CAGR of 9.6% from 2018 to 2025.
North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017, and is expected to dominate the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Benign Prostatic Hyperplasia Therapeutics Market Expected to Reach $20,097 million by 2025 here
News-ID: 2151848 • Views: โฆ
More Releases from Allied Market Research
Driving Innovation : Automotive Hypervisor Market to Hit $2.04 Billion by 2030, โฆ
According to a recent report published by Allied Market Research, titled, "Automotive Hypervisor Market by Vehicle Type, Type, Level of Automation and Vehicle Class: Global Opportunity Analysis and Industry Forecast, 2021-2030," ๐๐ก๐ ๐ ๐ฅ๐จ๐๐๐ฅ ๐๐ฎ๐ญ๐จ๐ฆ๐จ๐ญ๐ข๐ฏ๐ ๐ก๐ฒ๐ฉ๐๐ซ๐ฏ๐ข๐ฌ๐จ๐ซ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญ $๐๐๐.๐๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐, ๐๐ง๐ ๐ข๐ฌ ๐ฉ๐ซ๐จ๐ฃ๐๐๐ญ๐๐ ๐ญ๐จ ๐ซ๐๐๐๐ก $๐,๐๐๐.๐๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, ๐ซ๐๐ ๐ข๐ฌ๐ญ๐๐ซ๐ข๐ง๐ ๐ ๐๐๐๐ ๐จ๐ ๐๐.๐% ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐.
North America dominates the market in terms of revenue, followedโฆ
Driving Off the Beaten Path : Utility Terrain Vehicle Market to Reach $1.8 Billi โฆ
According to the report published by Allied Market Research, ๐๐ก๐ ๐ ๐ฅ๐จ๐๐๐ฅ ๐ฎ๐ญ๐ข๐ฅ๐ข๐ญ๐ฒ ๐ญ๐๐ซ๐ซ๐๐ข๐ง ๐ฏ๐๐ก๐ข๐๐ฅ๐ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฌ๐ข๐ณ๐ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญ $๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐, ๐๐ง๐ ๐ข๐ฌ ๐ฉ๐ซ๐จ๐ฃ๐๐๐ญ๐๐ ๐ญ๐จ ๐ซ๐๐๐๐ก $๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, ๐ ๐ซ๐จ๐ฐ๐ข๐ง๐ ๐๐ญ ๐ ๐๐๐๐ ๐จ๐ ๐.๐% ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐.
๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ฏ๐๐ซ๐ฏ๐ข๐๐ฐ
A utility terrain vehicle (UTVs), also known as a utility task vehicle or side-by-side (SxS), is a specialized off-road vehicle designed for several utility and recreational purposes. UTVsโฆ
Speaking Up : Automotive Voice Recognition System Market Set to Reach $14.7 Bill โฆ
According to a new report published by Allied Market Research, titled, "Automotive Voice Recognition System Market," ๐๐ก๐ ๐ ๐ฅ๐จ๐๐๐ฅ ๐๐ฎ๐ญ๐จ๐ฆ๐จ๐ญ๐ข๐ฏ๐ ๐ฏ๐จ๐ข๐๐ ๐ซ๐๐๐จ๐ ๐ง๐ข๐ญ๐ข๐จ๐ง ๐ฌ๐ฒ๐ฌ๐ญ๐๐ฆ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฌ๐ข๐ณ๐ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญ $๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐, ๐๐ง๐ ๐ข๐ฌ ๐ฉ๐ซ๐จ๐ฃ๐๐๐ญ๐๐ ๐ญ๐จ ๐ซ๐๐๐๐ก $๐๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, ๐ ๐ซ๐จ๐ฐ๐ข๐ง๐ ๐๐ญ ๐ ๐๐๐๐ ๐จ๐ ๐๐.๐% ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐.
๐
๐ฎ๐ญ๐ฎ๐ซ๐ข๐ฌ๐ญ๐ข๐ ๐๐ซ๐๐ง๐๐ฌ ๐๐ง๐ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ๐ฌ
Key trends impacting the automotive voice recognition system market:
> ๐๐ง๐ก๐๐ง๐๐๐ ๐๐ฌ๐๐ซ ๐๐ง๐ ๐๐ ๐๐ฆ๐๐ง๐ญ -
The automotive industry prioritizes user satisfaction,โฆ
Electric Truck Market to Reach $3.86 Billion by 2030 with a 26.4% CAGR - Industr โฆ
Allied Market Research (AMR) has recently published a comprehensive report entitled "Electric Truck Market." According to a research report, ๐๐ก๐ ๐ ๐ฅ๐จ๐๐๐ฅ ๐๐ฅ๐๐๐ญ๐ซ๐ข๐ ๐ญ๐ซ๐ฎ๐๐ค ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญ $๐๐๐.๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐, ๐๐ง๐ ๐ข๐ฌ ๐ฉ๐ซ๐จ๐ฃ๐๐๐ญ๐๐ ๐ญ๐จ ๐ซ๐๐๐๐ก $๐,๐๐๐.๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, ๐ซ๐๐ ๐ข๐ฌ๐ญ๐๐ซ๐ข๐ง๐ ๐ ๐๐๐๐ ๐จ๐ ๐๐.๐% ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐.
This research report provides a qualitative and quantitative analysis of recent technological developments, market dynamics, segmental analysis, regional analysis, key investmentโฆ
More Releases for Benign
Benign Prostatic Hyperplasia Therapeutics Market Clinical Survey Report 2020
The Benign Prostatic Hyperplasia Therapeutics Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Click the linkโฆ
Benign prostatic hyperplasia: BPH drugs versus Dr Allenโs Device
The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.
Thermobalancing therapy with Dr Allenโs Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allenโs Device.โฆ
Cold Plasma Market Benign Rate by 2025
Global Cold Plasma Market: Snapshot
Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasmaโordinarily known as the fourth condition of issueโwhich has gas particles show at direct temperature and electrons at moderately high temperatures. The properties of plasma have been widely looked into in the course of recent decades and an extensive number of front line utilizations of cold plasma innovation has exuded.
Cold plasma isn't inโฆ
Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, โฆ
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grantsโฆ
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
ReportsWorldwide has announced the addition of a new report title Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market to its growing collection of premium market research reports.
This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for BPH and prostatitis treatment devices.
Topics Covered Include:
An overview of device-based and pharmacological therapies for BPH and prostatitis.
Global and country/region-specific market forecasts, including forecasts by product segment.
Competitive analysesโฆ
Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2 โฆ
2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, aโฆ